Able Laboratories to Present at UBS Warburg Specialty Pharmaceuticals Conference.Business Editors & Health/Medical Writers SOUTH PLAINFIELD, N.J.--(BW HealthWire)--May 23, 2002 Able Laboratories, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ABRX) (BSE See Bombay Stock Exchange. BSE See Boston Stock Exchange (BSE). :ABRX) today announced that management will present at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg Global Specialty Pharmaceuticals Conference on Thursday, June 6, 2002 at 8:30 a.m. Eastern Time. The conference will be held at the Grand Hyatt New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of and Jay Wadekar, President and Chief Executive Officer of Able Laboratories, will be presenting for the Company. Able Laboratories' presentation can be heard live on the Internet. In addition, an audio replay will be available 24 hours after the presentation and will be available until July 6, 2002. Please visit www.ubswarburg.com and find the conference highlights link on the right hand side of the page. Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Since March 2001, Able has received 13 ANDA ANDA abbr. abbreviated new drug application approvals and one approvable letter from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . The Company has completed its transition to focus its activities primarily on generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. development, manufacturing and sales. Further information on Able may be found on the Company's Web site, www.ablelabs.com. Except for historical facts, the statements in this news release, as well as oral statements or other written statements made or to be made by Able Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and involve risks and uncertainties. For example, statements about the Company's anticipated growth and future operations, the current or expected market size for its products, the success of current or future product offerings, the research and development efforts and the Company's ability to file for and obtain U.S. Food and Drug Administration approvals for future products, are forward-looking statements. Forward-looking statements are merely the Company's current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that ANDA filings and approvals will be completed and obtained as anticipated. For a description of additional risks, and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2001 and its Form 10-Q for the quarter ended March 31, 2002. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion